Boulder, Colorado – April 27, 2018- Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy human volunteers. BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome. Demonstration that the…
Read more
About: admbbt
Recent Posts by admbbt
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome
BOULDER, Colo., Aug. 2, 2017 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015. The trial is designed to study the pharmacokinetics, pharmacodynamics, safety and tolerability of single subcutaneous doses of BBT-015 in healthy human subjects. BBT-015 is…
Read more
Study: The ability of granulocyte-macrophage colony stimulating factor (GM-CSF) to reverse Alzheimer’s disease and cognitive impairment in a mouse model of Alzheimer’s Disease
9 News in Denver, Colorado aired a series of reports highlighting recent progress in the fight against Alzheimer’s Disease. One of the reports focused on studies led by Huntington Potter, Ph.D., Professor of Neurology and Director of Alzheimer’s Disease Research in the Department of Neurology and the Linda Crnic Center for Down Syndrome at the…
Read more
U.S. Department of Defense to Fund Research at Indiana University and Epistem UK Investigating Treatments for Radiation Sickness
MANCHESTER, UNITED KINGDOM - (Marketwired - Nov 11, 2015) - Epistem Holdings Plc (LSE:EHP) ("Epistem" or "the Company"), the personalised medicine and biotechnology company, which has expertise evaluating treatments for gastrointestinal damage following radiation exposure, and Indiana University, with complementary experience evaluating treatments for similar bone marrow toxicity, today announced that they have received funding from…
Read more
Recent Comments by admbbt
No comments by admbbt yet.